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Abstract: Thyroid stimulating antibodies (TSAB) cause Graves’ disease and contribute to Graves’
Orbitopathy (GO) pathogenesis. We hypothesise that the presence of TSH binding proteins (truncated
TSHR variants (TSHRv)) and/or nonclassical ligands such as thyrostimulin (α2β5) might provide a
mechanism to protect against or exacerbate GO. We analysed primary human orbital preadipocyte-
fibroblasts (OF) from GO patients and people free of GO (non-GO). Transcript (QPCR) and protein
(western blot) expression levels of TSHRv were measured through an adipogenesis differentiation
process. Cyclic-AMP production by TSHR activation was studied using luciferase-reporter and RIA
assays. After differentiation, TSHRv levels in OF from GO were significantly higher than non-GO
(p = 0.039), and confirmed in ex vivo analysis of orbital adipose samples. TSHRv western blot
revealed a positive signal at 46 kDa in cell lysates and culture media (CM) from non-GO and GO-
OF. Cyclic-AMP decreased from basal levels when OF were stimulated with TSH or Monoclonal
TSAB (M22) before differentiation protocol, but increased in differentiated cells, and was inversely
correlated with the TSHRv:TSHR ratio (Spearman correlation: TSH r = −0.55, p = 0.23, M22 r = 0.87,
p = 0.03). In the bioassay, TSH/M22 induced luciferase-light was lower in CM from differentiated
GO-OF than non-GO, suggesting that secreted TSHRv had neutralised their effects. α2 transcripts
were present but reduced during adipogenesis (p < 0.005) with no difference observed between
non-GO and GO. β5 transcripts were at the limit of detection. Our work demonstrated that TSHRv
transcripts are expressed as protein, are more abundant in GO than non-GO OF and have the capacity
to regulate signalling via the TSHR.
Keywords: Graves’ Orbitopathy; thyrotropin receptor; variant; binding protein; thyrostimulin
1. Introduction
Graves’ Orbitopathy (GO) is a frequent clinical manifestation of Graves’ disease (GD)
with around 30–50% of patients being affected [1–4]. Rarely the GO is severe enough to lead
to blindness. There is a close association between GO and GD, implying an autoimmune
response to common antigen/s in the thyroid gland and orbit. Since the TSHR is found
to be expressed in orbital fat [5–8], and the majority of hyperthyroid patients with GO
have thyroid stimulating antibodies (TSAB), the receptor is the likely antigen candidate [9].
There is female preponderance towards GO, with a 6:1 female-to-male ratio. An increase in
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adipogenesis and hyaluronan production produces disfiguring exophthalmos and explains
the signs and symptoms of GO. Furthermore, most patients with GO have poor quality
of life [10] and suffer perpetual psychological distress due to the disfiguring appearance
of the exophthalmos [11]. Current managements for GO are sub-optimal, and further
research is needed to understand the pathophysiology of the condition. This will lead to
earlier diagnosis, thereby promoting preventative interventions and improving long-term
morbidity and socioeconomic impact.
We and others have demonstrated that activation of the thyrotropin receptor (TSHR)
in orbital preadipocyte-fibroblasts (OF) leads to increase in adipogenesis and hyaluronan
production [12,13]. During adipogenesis, TSHR expression has been shown to increase [5]
but little is known about the effects of TSHR activation at various differentiation stages.
Thyrostimulin, a nonclassical ligand for the TSHR has been described, it comprises α2
and β5 subunits [14]. It is suggested that it works via paracrine effects as it has not been
detected in the circulation as supported by the recent work of the Williams group in
bone [15]. Over-expression of α2 subunit in transgenic mice had no overt GO phenotype
but overexpression of β5 caused hyperthyroidism, weight loss and more importantly
exophthalmos [16]. These facts suggest it may have a role in GO pathogenesis.
Multiple TSHR variants (TSHRv) have been described. They lack the transmembrane
domain and if expressed as soluble receptor could serve as binding proteins to TSH, TSAB
and thyrostimulin. Their transcripts have been detected in OF and the thyroid gland [17].
Of interest, the exon 1–8 variant demonstrated similar structure to the TSHR A-subunit
which is generated following cleavage of the full length receptor [18,19]. Furthermore,
immunisation with TSHR A-subunit is more effective in murine models of GD and GO than
with the complete TSHR [20,21]. Thus these variants could have a role in GO pathogenesis
by inducing further production of TSAB or protect against GO by either inducing immune
reaction or ‘neutralising’ TSAB, respectively.
We have investigated the possible influence of thyrostimulin and TSHRv using in vitro
cell model and ex vivo analysis of orbital adipose tissues derived from people with GO
and non-GO controls.
2. Materials and Methods
All reagents were obtained from Sigma-Aldrich (Dorset, UK) and tissue culture com-
ponents from Cambrex (Thermo Fisher Scientific, Waltham, MA, USA) unless otherwise
stated.
2.1. Cells and Tissues Studied; In Vitro Culture and Ex Vivo Samples
Human Adipose Tissue was collected with informed written consent and approved by
the South East Wales Research Ethics Committee (30 May 2006) with registration number
(06/WSE03/37). Samples for in vitro studies were from five GO patients (two males and
three females), median age of 50 years (range 39–54 years) who were diagnosed on clinical
grounds based on the presence of typical clinical features and positive TSHR antibody.
The GO samples were obtained from patients with inactive disease (Clinical activity score
< 2) undergoing decompression surgery. Only one patient had had steroid therapy and
was on the treatment during orbital decompression. None of these patients had previous
orbital radiotherapy. The non-GO control samples (n = 5; three males and two females,
median age 53 years old (range 52–60 years) were from individuals free of thyroid or other
inflammatory eye disease who underwent eye lid surgery for cosmetic reasons. OF cells
for study were obtained from explant cultures as previously described [12]. Briefly, orbital
fat biopsies were diced and placed in six well plates in complete medium (CM, Hams
F12, Dulbecco’s Modified Eagle Medium, 10% foetal calf serum, Penicillin/Streptomycin,
pyruvate and bicarbonate) and allowed to attach so that OF migrated out from the tissue.
Once OFs were adherent, the plates were washed with culture media and OFs were grown
to confluence. The CM was replaced every three days. The cells were trypsinised and
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frozen in liquid nitrogen until further use. Cells were used at low passage number (≤ 3)
thus not every sample was used for each experiment.
Samples for ex vivo analysis comprised intact samples of orbital adipose tissues from
nine GO patients (three males and six females), median age of 45 years (range 32–71 years)
and five non-GO controls (All females), having a median age of 66 years (range 52–86
years). The tissue was snap frozen in liquid nitrogen directly following surgical removal.
Prior to RNA extraction they were pulverised in liquid nitrogen and then processed as
described below.
2.2. In Vitro Adipogenesis
The various cell populations were plated in six well plates in CM. Adipogenesis
was induced in confluent cells by replacing with differentiation medium (DM) containing
10% FCS, biotin (33 µM), pantothenate (17 µM), T3 (1 nM), dexamethasone (100 nM),
thiazolidinedione (1 µM), and insulin (500 nM) for 15 days. Adipogenesis was quantified
by measuring transcripts for terminal markers of differentiation lipoprotein lipase (LPL) by
quantitative PCR (Q-PCR).
2.3. QPCR Analysis
RNA was extracted using Tri Reagent (Sigma) from the OF and ex vivo samples
using RNA easy lipid tissue mini kit (Qiagen) according to the manufacturer’s instructions.
One µg RNA was reverse transcribed using oligodT and M-MLV reverse transcriptase
(Promega). cDNA was PCR amplified using primers in Table 1 for TSHR, TSHR variants
and thyrostimulin. TSHR (human NM_000369) could be distinguished from TSHRv isoforms
(human NM_001018036) by using exon 9 and 10 primers that are not present in the truncated
isoforms and using unique sequence in intron 8 of the isoforms that are not present in
full length TSHR. Sequencing of the amplicon produced confirmed the specificity of the
primers for the different types of TSHR. Q-PCR was carried out using Brilliant II SYBR
green master mix (Agilent Technologies, Stockport, UK) and a Stratagene (La Jolla, CA,
USA) MX3000 light cycler. Levels were normalised against adenosine phosphatylribosome
transferase (APRT). Standard curves were created using the relevant PCR product cloned
into pGEM T-easy (Promega, Southampton, UK) except for TSHRv (serial dilutions of
quantified PCR amplicon were used) to calculate the copy number/1000 APRT copies
(APRT expression has been previously shown to be unaffected by differentiation). In a
single Q-PCR experiment, all measurements were made in duplicate.
Table 1. Primer sequences used in the experiments for the TSHR isoforms and thyrostimulin subunits.
Accession Number Forward Reverse Amplicon Size (bp)
hAPRT NM_001030018.1 GCTGCGTGCTCATCCGAAAG CCTTAAGCGAGGTCAGCTCC 247
hLPL NC_000008.11 GAGATTTCTCTGTATGGACC CTGCAAATGAGACACTTTCTC 275
hTSHR NM_000369 GTGTCACTGCCCTTCCATCCA GGGGCTATTCAAGGCATTCACAGA 254
hTSHRv NM_001018036 CCTCCTAAAGTTCCTTGGCATT AGGACTTTCTTCCAAGAGGTAG 338
hα2 NM_130769.3 CTCGGAAGTGATGCCTATGGC CTAGTAGCGAGAGAGGCGAC 400
hβ5 AF403430 ATGAAGCTGGCATTCCTCTTC CTGTTGGGCAGCTTGACAGTC 296
2.4. Production of Antibody Specific for TSHRv
We used the 21 amino acid sequence derived from intron 8 of the TSHR, which is
unique to the 1.3kb TSHRv to generate a polyclonal antibody using a commercial company
(Generon, Slough, UK). A synthetic peptide was produced and coupled to keyhole limpet
haemocyanin and then used to immunise two rabbits. The resulting polyclonal antibodies
were affinity purified on the immunising peptide. We verified the specificity of each
antibody using western blots (described below) on the immunising peptide.
Curr. Issues Mol. Biol. 2021, 43 1797
2.5. Western Blot Analysis
Cell lysates from OF at various time points before and during adipogenesis were
obtained by addition of lysis buffer as previously described [13]. The culture supernatants
from the same time points were also collected and concentrated using spin columns (Merck
Millipore, Watford, Hertfordshire, UK) to produce an 80-fold concentration. Lysates and
concentrated supernatants were separated using SDS-PAGE as previously described [13].
Briefly, proteins were extracted, at various time points, in Laemmli buffer containing 1 mM
phenylmethylsulphonyl fluoride. Samples were separated by 10% SDS-PAGE and then
the gel electroblotted onto PVDF membrane. The blots were probed using antibodies to
the full length TSHR (2C11, Santa Cruz Biotechnology, Heidelberg, Germany) and TSHRv
antibody, at dilutions of 1:200 and 1:50 respectively at 4 ◦C overnight. This was followed by
a sheep anti-mouse IgG-HRP (1:5000, room temperature for 1 h, GE Healthcare) or donkey
anti-rabbit IgG-HRP conjugate (1:5000, room temperature for 1 h, GE Healthcare) and
then visualised by enhanced chemiluminescence using ECL Plus (Amersham Pharmacia
Biotech, Buckinghamshire, UK). They were then stripped and reprobed with antibodies to
housekeeping protein, actin at dilution of 1:1000 4 ◦C overnight with secondary anti-rabbit
as above.
2.6. Measurement of TSHR Activation
TSHR activation was measured in two different contexts. In the direct assay, OF were
cultured in 12 well plates at various time points before and during adipogenesis. Prior to
the assay they were switched to serum free medium for 24 h and then treated with IBMX
10−4 M alone or combined with bovine TSH 5 mu/mL or monoclonal TSAB (M22, RSR)
0.2 ng/µL 37 ◦C for 4 h. The cells were then lysed using HCl (0.1 M) and the cAMP in the
lysate measured using an in-house radio-immunoassay, as previously described [22].
In the indirect assay, culture supernatants from OF before and at various time points
during adipogenesis were collected as described above. The supernatants were then added
to TSH or M22 whilst they were assayed using an in-house luciferase bioassay as previously
described [23]. Briefly, 2 × 104 lulu (CHO cells expressing the full-length human TSHR
and a cAMP-responsive luciferase reporter) and zulu (CHO cells expressing the cAMP-
responsive luciferase reporter but not the TSHR) were plated in triplicates in 96 well plates
in complete medium for 48 h prior to assay. On the day of assay, the cells were washed
with PBS and culture supernatants added with or without (control) TSH or M22. This
was incubated at 37 ◦C for 5 h prior to addition of passive lysis buffer (Promega) and
frozen at −80 ◦C prior to analysis. The analysis was performed with luciferase assay
reagent (Promega, Madison, WI, USA) using Glomax Multidetection System (Promega).
Stimulation index was calculated by dividing mean of lulu* light unit for each sample by
the mean of zulu light unit.
2.7. Statistical Analysis
For statistical analysis, we used SPSS 18.0 software. Where appropriate, data were
analysed using Student’s t test for parametric and Mann-Whitney for nonparametric. A
paired t-test and One-way ANOVA with post-hoc Tukey were carried out where indicated.
In all cases, p < 0.05 was considered significant. The statistical analysis applied is indicated
in the tables and figure legends. All parametric data are presented as mean ± sem and
median ± interquartile range for nonparametric.
3. Results
3.1. TSHRv Transcripts Are Expressed at Higher Levels than Full-Length TSHR
Adipogenesis in OF was induced in about 10% of cells and, as in previous reports [24],
we observed that GO OF cells had higher adipogenic capacity than those from non-GO
patients (Supplementary Figure S1).
During adipogenesis, the full-length TSHR expression increased. There was no signifi-
cant difference between GO and non-GO full-length TSHR expression as shown in Figure
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1A. The TSHRv transcripts were expressed at higher levels than the complete receptor and
its level increased during differentiation, as shown in Figure 1B. Furthermore, the TSHRv
transcripts were expressed at significantly higher levels in GO than non-GO, possibly
reflecting the higher adipogenic potential of these cells. As a result, the ratio of TSHRv to
TSHR varied between 5 and 25 but was highly variable, so that no significant difference






Figure 1. The full length TSHR (A) and the TSHRv (B) transcripts were measured in GO (Stippled
bar, n = 5) and non-GO OF (Grey bar, n = 5) at multiple time points before (Day 0) and during
adipogenesis (Day 5, 10, 15). Results are expressed as transcript copy number of TSHR or TSHRv
per 1000 copies of the housekeeper APRT. Results are expressed as mean ± SEM; * p-value < 0.05,
** < 0.01 compared to day 0 on each respective day. Horizontal bars represent comparison between
non-GO and GO.
3.2. There Is No Role of Thyrostimulin in GO
Thyrostimulin α2 transcripts were detected in OF. There was a reduction in transcript
levels during adipogenesis (p < 0.05) (Supplementary Figure S2) with no difference was
found between non-GO and GO OF. In contrast β5 transcripts were not detected.
3.3. Transcripts Expression of Thyrostimulin and TSHRv in Ex Vivo Samples
Ex vivo analysis were performed on orbital adipose tissues after surgical removal.
TSHRv transcripts were detected with no differential effect between non-GO and GO.
Similar to in vitro cultures’ finding, the TSHRv transcripts were more abundant than full
length TSHR (Supplementary Figure S3) and the TSHRv:TSHR ratio was no different.
We confirmed the findings of in vitro cultures that α2 transcripts of thyrostimulin were
detected in the ex vivo samples while β5 transcripts were undetectable and there was no
difference between GO and non-GO.
3.4. TSHRv and TSHR Protein Are Detectable in OF
We generated an antibody specific for the TSHRv (Supplementary Figure S4). We then
performed western blots analyses on concentrated culture supernatants and cell lysates a
from non-GO and GO OF. We detected a protein with an apparent molecular mass of 46 kD
in the cell lysates and culture supernatants from OF (Figure 2A). This is consistent with
the TSHRv, which consists of 253 amino acids and retains five of the six putative N-linked
glycosylation sites present in the full-length TSHR. The doublet signals may represent
differing amounts of protein glycosylation. Its presence in the conditioned culture medium
suggests that it can be secreted from cells.
Similar to the transcript findings, the protein levels increased in samples prior to and
after adipogenesis. There was a stronger signal in the GO samples compared with non-GO,
both in the cell lysates and conditioned culture medium. Using 2C11 antibody (which
detects full length TSHR), we also demonstrated that the full length TSHR protein with an
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apparent molecular mass of 62kD was present in the cell lysates after adipogenesis and
higher in GO than non-GO Figure 2B (n = 3).
 
Figure 2. Western blot analysis of OF lysates and supernatants at baseline (D0) and after adipogenesis
(DM15) from a GO patient (GO) and non-GO (NO); (A) antibody to TSHRv (B) 2C11 antibody to
full-lengthTSHR. Neg; negative control (Secondary antibody only).
3.5. Is the TSHRv Functional?
cAMP productions were measured in response to a human monoclonal TSAB (M22)
and TSH at multiple time points before (basal, day 0) and after differentiation (day 15) of
OF. At basal levels, we noted a decrease in cAMP production when OF were stimulated
with M22 or TSH in GO compared to no-change in non-GO (p-value < 0.05). The opposite
was noted in differentiated cells, where there was an increase in cAMP following M22 or
TSH treatment, as shown in Table 2. The difference between GO and non-GO was not
significant.
Table 2. cAMP response (expressed in fold changes from unstimulated samples, Stimulation Index
(SI)) in OF pre (day0) and post-adipogenesis (day 15) in response to TSH 5 mU/mL and M22
0.2 ng/µL. Results are expressed as median ± interquartile range. NO, non-GO (NO); GO, Graves’
Orbitopathy.
Day of Culture Treatment
cAMP Stimulation Index (SI)
NO GO
Day 0
TSH 1.30 ± 0.11 0.29 ± 0.08 *
M22 0.84 ± 0.03 0.75 ± 0.02 *
Day 15
TSH 3.93 ± 1.64 1.55 ± 0.45
M22 1.89 ± 0.15 1.05 ± 0.28
* Mann-Whitney, p-value < 0.05 GO compared to non-GO.
Through adipogenesis, the amount of cAMP generated was negatively associated
with TSHRv:TSHR transcripts ratio (Figure 3) but this achieved significance only for M22
(Spearman correlation: TSH r = −0.55, p = 0.23, M22 r = 0.87, p = 0.03).
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−
Figure 3. cAMP stimulation index (SI) was negatively associated with TSHRv:TSHR transcripts ratio.
The ability of conditioned medium from OF’s before and after differentiation to
interfere with M22 or TSH induced TSHR activation was assessed in a luminescent bioassay.
Standard assay was performed in serum-free medium and both M22 and TSH induced
a dose-dependent stimulation index (S.I. as detailed in Method section) as shown in
Supplementary Figure S5.
We then used basal (day 0) conditioned medium (serum-free) from confluent cells prior
to addition of differentiation medium as the baseline S.I. There was no significant difference
in TSH-induced S.I. between non-GO and GO conditioned medium from undifferentiated
cells at day 0 (D0) and day 15 (CM15). At the end of adipogenesis (from differentiated cells,
DM15), the TSH-induced S.I. was lower in GO conditioned medium but not in non-GO, in
correlating with the abundance of TSHRv in GO. In the experiment using M22 we noted
that the S.I was lower in GO than non-GO at day 0 and after differentiation (Figure 4).
−
 
Figure 4. Luminescent bioassay to measure cAMP following TSHR activation. Indirect assays to
determine whether the TSHRv is functional were conducted using OF conditioned medium at various
stages of differentiation (cells at D0 = Day 0 in complete medium, CM15 = complete medium for
15 days culture, DM15 = Differentiation medium for 15 days) in the presence of TSH/M22. Results are
expressed as mean ± SEM; * p-value < 0.05, ** p-value < 0.01. Horizontal bars represent comparison
between non-GO (grey) and GO (striped).
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4. Discussion
We showed that thyrostimulin is unlikely to play a role in the orbit, although we could
not exclude thyrostimulin production [14] by other orbital components not studied. Our
results are consistent with those of Lantz et al., who also investigated orbital tissues [25].
Both orbital studies contrast with the work of Sun et al., who showed that thyrostimulin
functions as an ovarian paracrine regulator [26], and also of Bassett et al., who reported
the regulation of osteoblast formation in bone by thyrostimulin in early life [15]. Tissue
distribution analyses showed that the α2 subunit exhibits a broader distribution than the β5
subunit; however, both transcripts were found to be expressed in human retina, pituitary,
skin and testis [16,27]. Whilst it still possible that α2 can act as monomer or heteromerise
with unknown ligands, current animal model data does not support this hypothesis [16,28].
Our study demonstrated that the TSHRv was more abundant than the full length recep-
tor, and its expression increased during differentiation. The variant transcript is linked with
the reduction of cAMP stimulation index, which suggests that TSHR activation was altered
through interfering in TSH or TSAB binding by TSHRv. The activation of TSHR is clinically
correlated with the severity of GO [9]. Our study presents the autoregulation of TSHR
activity by TSHRv, which suggests a potential biomarker for GO. Further investigation is
needed. Previous thyroid tissue northern blot analysis identified the expected full-length
transcript plus two further transcripts at 1.3 and 1.6 kb [17]. We have demonstrated that
the more abundant of these TSHR isoforms, 1.3kb, is also present in other locations where
TSHR activation contributes to pathology, such as GO.
We confirmed our previous findings and those of others, i.e., that TSHR expression was
very low in undifferentiated OF and increased with adipogenesis. In contrast to previous
findings, we found no difference with regards to TSHR transcript expression between GO
and non-GO [5,29]. This discrepancy can be explained by different housekeeping gene and
experimental techniques used to quantify TSHR. We used quantitative PCR analysis in
which absolute numbers of TSHR transcripts were reported per APRT housekeeping gene;
this contrasts with Kumar et al., who reported relative quantification of the TSHR compared
to the 18S RNA [6,29]. It is well known that the use of different housekeeping genes will
influence the results of gene expression. However, our western blot analysis of full length
TSHR protein using 2C11 antibodies was in agreement with results published elsewhere,
despite using of different techniques (i.e., flow cytometry and immunocytochemistry
methods) [5,29,30].
We demonstrated that TSHR activation of undifferentiated OF (prior to the start of
adipogenesis) leads to a cAMP reduction, suggesting that the receptor is coupled to Gi
in these cells. Others have demonstrated different TSHR activation signalling via p70s6
kinase [31], which may result from Gq or Gs-beta/gamma signalling. To our knowledge,
this is the first report of the receptor coupling to an inhibitory G protein. This finding
addresses our previous failure to stimulate adipogenesis using gain-of-function mutants
of the TSHR [12], and is in agreement with a study by van Ziejl et al., who investigated
hyaluronan production using TSH/TSAB [32]. However, our finding contrasts with the
studies of Neumann and colleagues, who demonstrated an increase in M22-mediated
cAMP production, even at baseline. Of note, these authors maintained their OF in a
semi-adipogenic medium, which may have contributed to increased TSHR expression [33].
The TSHRv we used in our experiments was composed of 253 amino acids, and was
predicted to have five of the six N-linked glycosylation sites. Previous studies by Rapoport
and colleagues showed that a TSHR truncated to 261 amino acids was unable to bind
TSH [34]. The TSHR receptor contains nine leucine rich repeat (LRR) regions which have
been shown to act as the binding sites for TSH/TSAB [35]. Two of the LRR are located in
exon 9, but the unique sequence of 22 amino acids contributed by intron 8 are likely to be
sufficient to complete the 8th LRR, and thus, to enable this variant to bind TSH/TSAB.
The TSHR variant could act in several ways: (i) As a TSHR/TSAB binding protein
to neutralise their effects and inhibit TSHR activation, as suggested in the current study;
(ii) A potent autoantigen which could attract T cells to the orbit and contribute to the
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GO pathology; (iii) Since most GD/GO patients have a mixture of TSAB and TSHR-
blocking antibodies (TBABs) which bind preferentially to the N’ and C’ termini of the LRR,
respectively, the variant might bind TBAB, and thus, allow TSAB to predominate.
Regulation of TSHR alternative splicing is generally unknown. Proximal TSHR promo-
tor or intron 1 single-nucleotide polymorphisms (SNP) have been associated with increased
levels of the TSHR variant in thyroid tissue and thymus, with a consequent impact on
central tolerance mechanisms [36]. However GD patients with GO have not been shown
to have a higher prevalence of disease-associated TSHR intronic SNP than GD patients
without GO.
In summary, we showed that thyrostimulin does not present in orbital adipose tissue.
Both TSHR and TSHRv are present in the orbit, and TSHRv are more abundant than
full length TSHR in GO compared to non-GO from both in vitro and ex vivo analyses.
Secreted TSHRv was detected, which may alter intracellular TSHR signalling through
cAMP production and impact GO pathogenesis.
Supplementary Materials: Supplementary materials can be found at https://www.mdpi.com/
article/10.3390/cimb43030126/s1. Contain five supplementary figures published online alongside
this manuscript.
Author Contributions: Conceptualisation, M.S.D., F.G.-J., L.Z. and M.L.; Investigation, M.S.D. and
F.G.-J.; Resources, P.T., I.M., S.E., A.H., D.S.M., D.A.R. and C.L.; Writing—original draft, M.S.D.;
Writing—review and editing, C.D., L.Z. and M.L. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of
Human Adipose Tissue was collected with informed written consent and approved by the South
East Wales Research Ethics Committee (30 May 2006) with registration number (06/WSE03/37).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the
study.
Data Availability Statement: The data presented in this study as in Figures 1–4, Tables 1 and 2 and
Supplementary Figures S1–S5.
Acknowledgments: The authors thank patients, who provided samples used for this study.






TSAB Thyroid stimulating antibodies
GD Graves’ disease
References
1. Reddy, S.V.; Jain, A.; Yadav, S.B.; Sharma, K.; Bhatia, E. Prevalence of Graves’ ophthalmopathy in patients with Graves’ disease
presenting to a referral centre in north India. Indian J. Med. Res. 2014, 139, 99–104.
2. Tellez, M.; Cooper, J.; Edmonds, C. Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin. Endocrinol.
1992, 36, 291–294. [CrossRef] [PubMed]
3. Wiersinga, W.M.; Bartalena, L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002, 12, 855–860. [CrossRef]
4. Tanda, M.L.; Piantanida, E.; Liparulo, L.; Veronesi, G.; Lai, A.; Sassi, L.; Pariani, N.; Gallo, D.; Azzolini, C.; Ferrario, M.; et al.
Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism
seen at a single center. J. Clin. Endocrinol. Metab. 2013, 98, 1443–1449. [CrossRef] [PubMed]
Curr. Issues Mol. Biol. 2021, 43 1803
5. Crisp, M.; Starkey, K.J.; Lane, C.; Ham, J.; Ludgate, M. Adipogenesis in thyroid eye disease. Investig. Ophthalmol. Vis. Sci. 2000, 41,
3249–3255.
6. Kumar, S.; Coenen, M.J.; Scherer, P.E.; Bahn, R.S. Evidence for enhanced adipogenesis in the orbits of patients with Graves’
ophthalmopathy. J. Clin. Endocrinol. Metab. 2004, 89, 930–935. [CrossRef] [PubMed]
7. Bahn, R.S.; Dutton, C.M.; Natt, N.; Joba, W.; Spitzweg, C.; Heufelder, A.E. Thyrotropin receptor expression in Graves’ orbital
adipose/connective tissues: Potential autoantigen in Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 1998, 83, 998–1002.
[CrossRef]
8. Roselli-Rehfuss, L.; Robbins, L.S.; Cone, R.D. Thyrotropin receptor messenger ribonucleic acid is expressed in most brown and
white adipose tissues in the guinea pig. Endocrinology 1992, 130, 1857–1861.
9. Khoo, D.H.; Ho, S.C.; Seah, L.L.; Fong, K.S.; Tai, E.S.; Chee, S.P.; Eng, P.H.; Aw, S.E.; Fok, A.C. The combination of absent thyroid
peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly
increased risk of ophthalmopathy. Thyroid 1999, 9, 1175–1180. [CrossRef]
10. Wiersinga, W.M. Quality of life in Graves’ ophthalmopathy. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26, 359–370. [CrossRef]
11. Coulter, I.; Frewin, S.; Krassas, G.E.; Perros, P. Psychological implications of Graves’ orbitopathy. Eur. J. Endocrinol. Eur. Fed.
Endocr. Soc. 2007, 157, 127–131. [CrossRef] [PubMed]
12. Zhang, L.; Baker, G.; Janus, D.; Paddon, C.A.; Fuhrer, D.; Ludgate, M. Biological effects of thyrotropin receptor activation on
human orbital preadipocytes. Investig. Ophthalmol. Vis. Sci. 2006, 47, 5197–5203. [CrossRef] [PubMed]
13. Zhang, L.; Paddon, C.; Lewis, M.D.; Grennan-Jones, F.; Ludgate, M. Gsalpha signalling suppresses PPARgamma2 generation and
inhibits 3T3L1 adipogenesis. J. Endocrinol. 2009, 202, 207–215. [CrossRef] [PubMed]
14. Nakabayashi, K.; Matsumi, H.; Bhalla, A.; Bae, J.; Mosselman, S.; Hsu, S.Y.; Hsueh, A.J. Thyrostimulin, a heterodimer of two new
human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor. J. Clin. Investig. 2002, 109, 1445–1452.
[CrossRef] [PubMed]
15. Bassett, J.H.; van der Spek, A.; Logan, J.G.; Gogakos, A.; Bagchi-Chakraborty, J.; Murphy, E.; van Zeijl, C.; Down, J.; Croucher, P.I.;
Boyde, A.; et al. Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development. Endocrinology 2015,
156, 3098–3113. [CrossRef]
16. Okada, S.L.; Ellsworth, J.L.; Durnam, D.M.; Haugen, H.S.; Holloway, J.L.; Kelley, M.L.; Lewis, K.E.; Ren, H.; Sheppard, P.O.;
Storey, H.M.; et al. A glycoprotein hormone expressed in corticotrophs exhibits unique binding properties on thyroid-stimulating
hormone receptor. Mol. Endocrinol. 2006, 20, 414–425. [CrossRef]
17. Paschke, R.; Metcalfe, A.; Alcalde, L.; Vassart, G.; Weetman, A.; Ludgate, M. Presence of nonfunctional thyrotropin receptor
variant transcripts in retroocular and other tissues. J. Clin. Endocrinol. Metab. 1994, 79, 1234–1238.
18. Quellari, M.; Desroches, A.; Beau, I.; Beaudeux, E.; Misrahi, M. Role of cleavage and shedding in human thyrotropin receptor
function and trafficking. Eur. J. Biochem. 2003, 270, 3486–3497. [CrossRef] [PubMed]
19. Rapoport, B.; McLachlan, S.M. The thyrotropin receptor in Graves’ disease. Thyroid 2007, 17, 911–922. [CrossRef]
20. Zhao, S.X.; Tsui, S.; Cheung, A.; Douglas, R.S.; Smith, T.J.; Banga, J.P. Orbital fibrosis in a mouse model of Graves’ disease induced
by genetic immunization of thyrotropin receptor cDNA. J. Endocrinol. 2011, 210, 369–377. [CrossRef]
21. Moshkelgosha, S.; So, P.W.; Diaz-Cano, S.; Banga, J.P. Preclinical models of Graves’ disease and associated secondary complications.
Curr. Pharm. Des. 2015, 21, 2414–2421. [CrossRef] [PubMed]
22. Fuhrer, D.; Lewis, M.D.; Alkhafaji, F.; Starkey, K.; Paschke, R.; Wynford-Thomas, D.; Eggo, M.; Ludgate, M. Biological activity of
activating thyroid-stimulating hormone receptor mutants depends on the cellular context. Endocrinology 2003, 144, 4018–4030.
[CrossRef] [PubMed]
23. Evans, C.; Morgenthaler, N.G.; Lee, S.; Llewellyn, D.H.; Clifton-Bligh, R.; John, R.; Lazarus, J.H.; Chatterjee, V.K.; Ludgate,
M. Development of a luminescent bioassay for thyroid stimulating antibodies. J. Clin. Endocrinol. Metab. 1999, 84, 374–377.
[CrossRef] [PubMed]
24. Draman, M.S.; Grennan-Jones, F.; Zhang, L.; Taylor, P.N.; Tun, T.K.; McDermott, J.; Moriarty, P.; Morris, D.; Lane, C.; Sreenan,
S.; et al. Effects of prostaglandin F(2alpha) on adipocyte biology relevant to graves’ orbitopathy. Thyroid 2013, 23, 1600–1608.
[CrossRef] [PubMed]
25. Lantz, M.; Vondrichova, T.; Capretz, A.; Nilsson, E.; Frenander, C.; Bondeson, A.G.; Ridderstrale, M.; Aberg, M.; Asman, P.; Groop,
L.; et al. Thyrostimulin (a TSH-like Hormone) expression in orbital and thyroid tissue. Thyroid 2007, 17, 113–118. [CrossRef]
[PubMed]
26. Sun, S.C.; Hsu, P.J.; Wu, F.J.; Li, S.H.; Lu, C.H.; Luo, C.W. Thyrostimulin, but not thyroid-stimulating hormone (TSH), acts as a
paracrine regulator to activate the TSH receptor in mammalian ovary. J. Biol. Chem. 2010, 285, 3758–3765. [CrossRef]
27. Bodo, E.; Kromminga, A.; Biro, T.; Borbiro, I.; Gaspar, E.; Zmijewski, M.A.; van Beek, N.; Langbein, L.; Slominski, A.T.; Paus, R.
Human female hair follicles are a direct, nonclassical target for thyroid-stimulating hormone. J. Investig. Dermatol. 2009, 129,
1126–1139. [CrossRef]
28. Nagasaki, H.; Wang, Z.; Jackson, V.R.; Lin, S.; Nothacker, H.P.; Civelli, O. Differential expression of the thyrostimulin subunits,
glycoprotein alpha2 and beta5 in the rat pituitary. J. Mol. Endocrinol. 2006, 37, 39–50. [CrossRef] [PubMed]
29. Starkey, K.J.; Janezic, A.; Jones, G.; Jordan, N.; Baker, G.; Ludgate, M. Adipose thyrotrophin receptor expression is elevated in
Graves’ and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J. Mol. Endocrinol. 2003, 30, 369–380.
[CrossRef] [PubMed]
Curr. Issues Mol. Biol. 2021, 43 1804
30. Valyasevi, R.W.; Erickson, D.Z.; Harteneck, D.A.; Dutton, C.M.; Heufelder, A.E.; Jyonouchi, S.C.; Bahn, R.S. Differentiation of
human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J. Clin. Endocrinol. Metab. 1999, 84,
2557–2562. [CrossRef]
31. Bell, A.; Gagnon, A.; Grunder, L.; Parikh, S.J.; Smith, T.J.; Sorisky, A. Functional TSH receptor in human abdominal preadipocytes
and orbital fibroblasts. Am. J. Physiol. Cell Physiol. 2000, 279, C335–C340. [CrossRef] [PubMed]
32. van Zeijl, C.J.; Fliers, E.; van Koppen, C.J.; Surovtseva, O.V.; de Gooyer, M.E.; Mourits, M.P.; Wiersinga, W.M.; Miltenburg, A.M.;
Boelen, A. Thyrotropin receptor-stimulating Graves’ disease immunoglobulins induce hyaluronan synthesis by differentiated
orbital fibroblasts from patients with Graves’ ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
Thyroid 2011, 21, 169–176. [CrossRef] [PubMed]
33. Neumann, S.; Pope, A.; Geras-Raaka, E.; Raaka, B.M.; Bahn, R.S.; Gershengorn, M.C. A Drug-Like Antagonist Inhibits Thyrotropin
Receptor–Mediated Stimulation of cAMP Production in Graves’ Orbital Fibroblasts. Thyroid 2012, 22, 839–843. [CrossRef]
[PubMed]
34. Chazenbalk, G.D.; Jaume, J.C.; McLachlan, S.M.; Rapoport, B. Engineering the human thyrotropin receptor ectodomain from a
non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves’ patients’ sera. J.
Biol. Chem. 1997, 272, 18959–18965. [CrossRef] [PubMed]
35. Nagayama, Y.; Wadsworth, H.L.; Russo, D.; Chazenbalk, G.D.; Rapoport, B. Binding domains of stimulatory and inhibitory
thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors. J. Clin.
Investig. 1991, 88, 336–340. [CrossRef] [PubMed]
36. Ploski, R.; Brand, O.J.; Jurecka-Lubieniecka, B.; Franaszczyk, M.; Kula, D.; Krajewski, P.; Karamat, M.A.; Simmonds, M.J.;
Franklyn, J.A.; Gough, S.C.; et al. Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for
Graves’ disease in three European Caucasian cohorts. PLoS ONE 2010, 5, e15512. [CrossRef]
